Fast forward to actionable results with rapid AST technology
19 Oct 2021
Gaining early access to antimicrobial susceptibility testing (AST) results for critically ill patients is key to optimizing treatment decisions and antimicrobial stewardship. In this webinar, join Dr. Tiziana Di Martino, Chief Medical Officer of Qlinea, to hear how clinical microbiology labs can fast forward to actionable results with a brand new rapid antimicrobial susceptibility testing technology, distributed exclusively by Thermo Fisher Scientific, designed to deliver accurate minimum inhibitory concentration (MIC) results in approximately 6 hours.
Key learning objectives:
- Gain an understanding of how clinical diagnostics are being used to address the dangers of sepsis and antimicrobial resistance (AMR), and improve standards of care for bloodstream infection patients
- Learn the impact rapid AST can have on patient care, ensuring the right person receives the right treatment at the right time
- Explore an exciting new rapid AST technology from Q-linea’s Chief Medical Officer, Dr. Tiziana Di Martino
Who should attend?
- Clinical microbiologists
- Laboratory managers
- Laboratory directors
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Thermo Fisher Scientific